Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy

Independent external validation of predictive models for urinary dysfunction following external beam radiotherapy of the prostate: Issues in model development and reporting

“…79 articles were found. Four articles [17][18][19][20] were selected after excluding other articles for at least one of these reasons; treated using brachytherapy (18) or protons (1), traditional explanatory studies (e.g. finding predictors, dosimetric constraints, comparisons between 3dimensional conformal radiotherapy to intensity modulated radiotherapy) (42), using nonurinary endpoints 7, non-radiotherapy (5), machine learning study with no access to the final model (1) and our own (1).…”

“…In total, 14 models were considered. Two of the studies produced predictive models for late urinary symptoms [17,18] and another two for acute urinary symptoms [19,20]. The studies and the associated models are listed in Table 1.…”

“…The endpoints for models from Mathieu et al were based on the LENT-SOMA scale while models from Cozzarini et al and Palorini et al were based on IPSS, both of which were directly comparable to the assessments used in the validation cohort [17,19,20]. De Langhe et al used an in-house developed scoring system.…”

Understanding Urinary Toxicity after Radiotherapy for Prostate Cancer: First Steps Forward

“…The International Prostate Symptoms Score (IPSS (28)) thus became widely used to score obstructive symptoms and generate an overall assessment of urinary functionality (15,(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42). Urinary incontinence can be prospectively assessed by the International Consultation on Incontinence Modular Questionnaire Short Form (ICIQ-SF (43)), which also includes the patient's perception of the impact of incontinence on quality of life (14,44).…”

“…This is particularly important for urinary toxicities. In the radical setting, there are some indications that hypofractionation may have a detrimental impact on urinary morbidity compared with conventional fractionation both in the acute and late stages (34,37,44,(66)(67)(68)(69)(70)(71). On the other hand, in trials prescribing lower 2-Gy-equivalent doses, no significant impact has been reported for acute and late urinary toxicity.…”